Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F, Werft W, Walter A, Keller S, Wang X, Benner A, Burwinkel B, Sinn P, Hug S, Sohn C, Bretz N, Moldenhauer G, Rupp C, Rupp AK, Biakhov MY, Bottini A, Friedrichs K, Khailenko VA, Manikhas GM, Ruiz A, Sánchez-Rovira P, Santoro A, Segui MA, Villena C, Lichter P, Kristiansen G, Altevogt P, Schneeweiss A. Marmé F, et al. Among authors: santoro a. Breast Cancer Res Treat. 2012 Apr;132(3):819-31. doi: 10.1007/s10549-011-1759-9. Epub 2011 Sep 30. Breast Cancer Res Treat. 2012. PMID: 21960110 Clinical Trial.
Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D, Frassineti GL, De Matteis A, Mustacchi G, Santoro A, Cariello S, Ferrari M, Nascimben O, Nanni O, Lombardi A, Scarpi E, Zoli W. Amadori D, et al. Among authors: santoro a. Breast Cancer Res Treat. 1998 Jun;49(3):209-17. doi: 10.1023/a:1006063412726. Breast Cancer Res Treat. 1998. PMID: 9776504 Clinical Trial.
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Conte PF, Donati S, Gennari A, Guarneri V, Orlandini C, Rondini M, Roncella M, Marini L, Collecchi P, Viacava P, Naccarato AG, Degli Esposti R, Bonardi S, Bottini A, Saracchini S, Tumolo S, Gullo G, Santoro A, Crino L. Conte PF, et al. Among authors: santoro a. Br J Cancer. 2005 Aug 22;93(4):406-11. doi: 10.1038/sj.bjc.6602723. Br J Cancer. 2005. PMID: 16052214 Free PMC article. Clinical Trial.
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Guarneri V, et al. Among authors: santoro a. Breast Cancer Res Treat. 2008 Jul;110(1):127-34. doi: 10.1007/s10549-007-9688-3. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687648 Free article. Clinical Trial.
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M. de Azambuja E, et al. Among authors: santoro a. Breast Cancer Res Treat. 2010 Jan;119(1):145-53. doi: 10.1007/s10549-009-0512-0. Breast Cancer Res Treat. 2010. PMID: 19731015 Clinical Trial.
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A. Zucali PA, et al. Among authors: santoro a. Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24. Clin Cancer Res. 2011. PMID: 21262916 Clinical Trial.
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Chirgwin J, et al. Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4. Breast Cancer Res Treat. 2012. PMID: 21892704 Free PMC article. Clinical Trial.
3,017 results